Reportstack

PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022

 

Naperville, IL -- (ReleaseWire) -- 01/14/2014 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022 market report to its offering
PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022

Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of 2012 to 2022 forecast, Sanofi/Regenerons dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Growth within that market will stem from the positive uptake of three therapies: cyclosporine, systemic antihistamines and the Japanese-manufactured topical calcineurin inhibitor, Astellas/Maruhos Protopic. Collectively, these three therapies will contribute $361.9m sales to the 2022.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Japan

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/148971/pharmapoint-atopic-dermatitis-japan-drug-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###